COMP <GO>
NUWE vs NDRA // ALTMAN Z-SCORE & DEBT/EQUITY
Nuwellis Inc. (NASDAQ) VS. ENDRA Life Sciences Inc. (NASDAQ) • 15-METRIC TALLY: NUWE 1
— NDRA 1
■ METRIC PARITY
LAST: $5.78 (+2.12%) • MKT CAP: $2.3M
balance-sheet
—
LAST: $4.88 (+2.95%) • MKT CAP: $7.3M
balance-sheet
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NUWE VS. NDRA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NUWE | NDRA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 62.00% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | -5.40% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 3/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 90.1 | 45.0 | +45.10 | NUWE | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.3M | $7.3M | -$5.0M | NDRA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NUWE REV | NDRA REV | NUWE GROSS % | NDRA GROSS % | NUWE FCF | NDRA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $8.3M | $0 | 62.0% | — | -$10.9M | -$5.2M |
| FY 2024 | $8.7M | $0 | 64.9% | — | -$9.7M | -$7.4M |
| FY 2023 | $8.9M | $0 | — | — | -$17.9M | -$9.5M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NUWE // BETA —
NDRA // BETA —